Brought to you by 
Acorda to gain late-stage diazepam spray through Neuronex acquisition
23 May 2016
Executive Summary
Acorda Therapeutics Inc. (neuromuscular disorders, multiple sclerosis, and cardiac function) has agreed to acquire Neuronex Inc., a private neurology drug in-licenser, for as much as $10mm initially plus up to a potential $123mm in earn-outs. Neuronex will become a wholly owned subsidiary.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Nasal
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Acorda to gain late-stage diazepam spray through Neuronex acquisition
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice